引用本文: | 胡进,许俊杰,傅伟达.氟哌噻吨美利曲辛片治疗继发性BPPV老年患者残余头晕症状的疗效观察[J].中国现代应用药学,2018,35(6):888-890. |
| HU Jin,XU Junjie,FU Weida.Cutative Effect of Flupentixol and Melitracen Tablets on Residual Diziness of Gerontal Patients with Secondary Benign Paroxysmal Positional Vertigo[J].Chin J Mod Appl Pharm(中国现代应用药学),2018,35(6):888-890. |
|
摘要: |
目的 探讨氟哌噻吨美利曲辛片对继发性良性阵发性位置性眩晕(bnign proxysmal psitional vrtigo,BPPV)老年患者残余头晕症状的影响。方法 收集2014年1月—2016年9月嘉兴市第一医院神经内科治疗的84例继发性BPPV老年患者(年龄>65周岁)的临床资料,分为氟哌噻吨美利曲辛片治疗组(n=42)和常规治疗组(n=42)。比较2组残余头晕的持续时间及治疗前,治疗后第3天、第1周、第2周的眩晕障碍量表(Dizziness Handicap Inventory,DHI)分数。结果 和常规治疗组相比,氟哌噻吨美利曲辛片治疗组残余头晕症状持续时间明显较短(P=0.002)。复位成功后,与常规治疗组相比,氟哌噻吨美利曲辛片组治疗后第1周和第2周的DHI分数明显降低(P分别为0.040和0.030)。结论 氟哌噻吨美利曲辛片治疗继发性BPPV,可使残余头晕的持续时间明显缩短,治疗1周和2周后DHI评分降低。 |
关键词: 氟哌噻吨美利曲辛片 继发性良性阵发性位置性眩晕 残余头晕 眩晕障碍量表 |
DOI:10.13748/j.cnki.issn1007-7693.2018.06.022 |
分类号:R969.4 |
基金项目:浙江省卫生适宜技术成果转化计划项目(2015ZHB013);嘉兴市第一医院壹计划项目(2017-YA-18) |
|
Cutative Effect of Flupentixol and Melitracen Tablets on Residual Diziness of Gerontal Patients with Secondary Benign Paroxysmal Positional Vertigo |
HU Jin1,2, XU Junjie2, FU Weida2
|
1.Zhejiang Chinese Medical University, Hangzhou 310053, China;2.department of internal neurology, the First Hospital of Jiaxing, Jiaxing 314000, China
|
Abstract: |
OBJECTIVE To investigate the influence of flupentixol and melitracen tablets in residual diziness of gerontal patients with secondary benign paroxysmal positional vertigo (BPPV). METHODS The clinical data of 84 gerontal patients (age >65) with secondary BPPV who received treatment in the neurology clinic of the First Hospital of Jiaxing were collected. These patients were divided into two groups:Flupentixol and melitracen tablets group (n=42) and conventional treatment group (n=42). The duration of residual diziness and the score of Dizziness Handicap Inventory (DHI) were analyzed before treatment, three days, one week and two weeks after treatment. RESULTS The duration of residual diziness in flupentixol and melitracen tablets group was shorter than conventional treatment group (P=0.002). Compared with conventional treatment group after resetting success, the score of flupentixol and melitracen tablets group significantly decreased for one week and two week after treatment (P=0.040 and P=0.030, respectively). CONCLUSION flupentixol and melitracen tablets group have shorter duration of residual diziness, lower score of DHI of one week or two weeks after treatment. |
Key words: Flupentixol and Melitracen tablets secondary benign paroxysmal positional vertigo residual diziness Dizziness Handicap Inventory |